Annual report
4671.TEDINET S100TPDE
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥43.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥43.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥43.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥941m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.7bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥36.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥37.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥32.0bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.4bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥26.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥20.5bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥18.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.1bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥3.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥322m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥448m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥151.72 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.61 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.87 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥150.9 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥177.54 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.06 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,431.22 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,362.21 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.14 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,966.43 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,776.01 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 71.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.8% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.4% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,117 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,159 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,179 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,200 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 1,249 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥3.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.8bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.9bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.4bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥1.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.7bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.5bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.8bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥806m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥2.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥26.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥24.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥24.2bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.3bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.1bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥22.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥23.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥20.1bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥18.0bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.6bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥10.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥171.85 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.04 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥254.07 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥96.55 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.11 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥170.92 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥216.76 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥252.56 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.97 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥117.29 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥115 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥64 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,138.28 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,063.91 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,914.28 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,726.33 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,621.07 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.3% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.4% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 11,080,177 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 2 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 2 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥694m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥243m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥20.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥456m |
| Clinical Testing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥558m |
| Clinical Testing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥572m |
| Clinical Testing Businessreportable segment | employees | at 2024-03-31 | 658 pure |
| Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥25.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥25.9bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| Clinical Testing Businessreportable segment | segment assets | at 2024-03-31 | ¥9.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥167m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥117m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2024-03-31 | 386 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥16.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥16.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥5.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥960m |
| ICT Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥88m |
| ICT Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥32m |
| ICT Businessreportable segment | employees | at 2024-03-31 | 48 pure |
| ICT Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| ICT Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| ICT Businessreportable segment | segment assets | at 2024-03-31 | ¥828m |
| ICT Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥142m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥814m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥721m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥43.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥43.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| —segment total | segment assets | at 2024-03-31 | ¥15.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥732m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥232m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥7m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥22.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥562m |
| Clinical Testing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥341m |
| Clinical Testing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥638m |
| Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥30.2bn |
| Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥30.1bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6m |
| Clinical Testing Businessreportable segment | segment assets | at 2023-03-31 | ¥10.3bn |
| Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.9bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥97m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥124m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥16.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥16.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥5.3bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥892m |
| ICT Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥40m |
| ICT Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥30m |
| ICT Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥794m |
| ICT Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥794m |
| ICT Businessreportable segment | segment assets | at 2023-03-31 | ¥707m |
| ICT Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥141m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥478m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥793m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥46.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥46.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7m |
| —segment total | segment assets | at 2023-03-31 | ¥16.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,553
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 0 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.338 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.361 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.598 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.641 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.999 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.882 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.228 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.223 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.259 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.739 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 658 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 1094 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 386 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 168 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E04982-000ICTBusinessReportableSegmentsMember | 48 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E04982-000ICTBusinessReportableSegmentsMember | 5 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 25 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 0 | |
| Number of employees | CurrentYearInstant | 1117 | |
| Average number of temporary workers | CurrentYearInstant | 1267 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 0 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 53.3 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 32.2 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7153961 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 4 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 0 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.000 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.571 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.676 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.773 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.853 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.250 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 1.00 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.550 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.763 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.450 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.143 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.560 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.568 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.606 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 1410000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 501000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 128000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04982-000ICTBusinessReportableSegmentsMember | 88000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11080177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11080177 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 11080177 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |